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Conclusions: BLEEDRS – an adapted simplification of HASBLED score predicts major
bleeding events after PCI.
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Background: Oxidation of lipoproteins generates multiple bioactive oxidized lipids that
affect atherothrombosis and endothelial dysfunction, but direct evidence of their role
during therapeutic procedures is lacking. Liberated oxidized lipids may result in no-reflow
phenomenon, myocardial infarction and stroke. To assess whether oxidized vasoactive
lipids are released downstream from atherosclerotic plaques following percutaneous
coronary and peripheral interventions we undertook a lipidomic analysis of material
recovered from distal embolic protection devices from different vascular beds.
Methods: The presence of specific oxidized lipids was assessed in embolized material
captured by distal embolic protection devices during saphenous vein graft, carotid, renal,
and superficial femoral artery interventions. Following lipid extraction, specific oxidized
phospholipids (OxPL) and cholesterol esters (OxCE) were quantified in 12 filters using
liquid chromatography, tandem mass spectrometry.
Results: Phosphatidylcholine (PC) containing OxPL, including 1-palmitoyl-2-(5-
oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC), C9 aldehyde PC, E2 and F2 iso-
prostane PC, and hydroperoxy PC were identified in the extracted lipid portion. The major
oxidized PC by mass was the C9 aldehyde PC, representing 38% of all oxidized PL.
Several species of OxCE, such as aldehyde, hydroperoxide, oxide and epoxy cholesterol
ester derivatives from cholesteryl linoleate and cholesteryl arachidonate, were also
present. The pattern of OxPL and OxCE within filters correlated well with molecules
found in various forms of oxidized LDL and did not differ significantly in different
vascular beds. The presence of OxPL was also confirmed using ELISA and immunohis-
tochemistry.
Conclusions: This is the first documentation of the presence and direct release of
oxidized lipids from atherosclerotic plaques during percutaneous interventions from
multiple vascular beds in humans. The release of such oxidized lipids into the microcir-
culation may mediate some of the adverse clinical outcomes that result during these
intravascular interventions.
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Background: An intra-coronary device becoming stuck is a very uncommon compli-
cation that may lead to tragic consequences such as occlusion of the artery and systemic
embolism.
Methods: Of 14,198 lesions in 13,188 patients who underwent PCI between 1999 and
2011, 40 device stuck (0.28%) incidents occurred during PCI procedures. The incidence,
outcomes and management of these device stuck occurrences were evaluated.
Results: The overall procedural success rate was 97.8% (13,884/14,198). The stuck
devices included stents (n20; 50%), wires (n14; 35%), balloons (n4; 10%),
intra-vascular ultrasound (n1; 2.5%), and rotablator burrs (n1; 2.5%), respectively.
Management of the complication and acute/long-term outcomes are shown in the table. Of
54 instances of device stuck, 15 (37.5%) were retrieved successfully, and 7 (18%)
resulted in rupture and were left in the coronary artery. Thirty-seven patients recovered in
the cath-lab and the rest (N3) were referred to emergency CABG. At 1-year follow-up,
all patients were alive, although the segment of the coronary artery where the device
stuck occurred was occluded in 2 cases on agiographic findings.
Conclusions: Although the rate of this complication during PCI was very low, all cases
were solved with optimal treatment and all patients survived at 1-year follow-up. A safe
procedure with careful device manipulation should be required for PCI, with appropriate
management leading to better outcomes.
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Background: Recent advances in antithrombotic therapy for STEMI are accompanied
by an increased risk of bleeding. So far, the CRUSADE score for bleeding risk has only
been validated in NSTEMI.
Methods: The risk of in-hospital major CRUSADE bleeding and 1-year mortality after
primary PCI for STEMI was studied in consecutive patients who received upfront
abciximab, periprocedural heparin and loading doses of aspirin and clopidogrel.
Results: In total, 965 STEMI patients (6112 yrs, 76% men) were stratified according
to the CRUSADE bleeding risk score (Table). Median CRUSADE score was 21 (14-29).
Bleeding was common (21%) ranging from 11% in the very low risk group up to 69% in
the very high risk group. Most common bleeding site was the femoral access site. In 3
patients, bleeding most likely led to death. Survival analysis demonstrated 1-year
mortality rates of 9.2% in bleeders vs. 2.5% in non-bleeders (p0.001, Figure).
Assessment of the CRUSADE risk score by ROC curve resulted in an area under the
curve of only 0.68 (0.64-0.73, p0.001).
CRUSADE bleeding risk score Non-bleeders Bleeders
Very low risk 399 (88.9%) 50 (11.1%)
Low risk 230 (75.9%) 73 (24.1%)
Moderate risk 95 (69.3%) 42 (30.7%)
High risk 39 (65.0%) 21 (35.0%)
Very high risk 5 (31.3%) 11 (68.8%)
In-hospital major bleeding in CRUSADE bleeding risk score categories
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